ARSENAULT KAITLYN 4/A
4/A · Skye Bioscience, Inc. · Filed Feb 28, 2025
Insider Transaction Report
Form 4/AAmended
ARSENAULT KAITLYN
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-11-18$4.99/sh−43,026$214,700→ 167,522 total - Sale
Common Stock
2024-11-15$5.55/sh−190$1,055→ 210,548 total
Footnotes (2)
- [F1]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.